Provention Bio, Inc.
DelistedCIK 1695357fmd_08DFGZ3K4GPBYBC53EQW1RRRRHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2016 to Dec 31, 2022, 24 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 1 | 13 |
| Research and development | 8 | 23 | 36 | 66 | 70 | 76 |
| Selling, general and administrative | – | – | – | 33 | 47 | 64 |
| Total operating expenses | 9 | 27 | 44 | 100 | 117 | 141 |
| Operating income | (9) | (27) | (44) | (100) | (116) | (128) |
| Interest expense | – | – | – | – | – | 1 |
| Interest and investment income | 0 | 1 | 1 | 1 | 0 | 2 |
| Income before taxes | (9) | (27) | (43) | (99) | (115) | (127) |
| Income tax expense | – | (0) | – | (1) | (1) | (13) |
| Net income from continuing operations | – | (26) | – | (99) | (114) | (114) |
| Net income | (9) | (26) | (43) | (99) | (114) | (114) |
| Net income to common shareholders | (9) | (27) | (43) | (99) | – | – |